This marks the first new ovarian cancer treatment approved for NHS use in two decades, offering a lifeline to patients whose disease is resistant to chemotherapy.
The targeted therapy, described as a “biological missile”, works by attaching to and destroying cancer cells, specifically for folate receptor-alpha-positive platinum-resistant epithelial cancers.
Clinical trials indicate the drug can improve survival by approximately four months on average compared to chemotherapy alone, benefiting around 400 patients in England annually.
Experts and patient advocates have hailed the “landmark” decision, highlighting its potential to significantly improve quality of life and provide additional options at a critical stage of the disease.
